ArticleHeart failure reviews2022
Atrial fibrillation-induced tachycardiomyopathy and heart failure: an underappreciated and elusive condition.
Article in Heart failure reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Cardiac arrhythmia detection via PQRST analyzed data using an optimized hierarchical fused fuzzy deep reinforcement learning.BMC medical informatics and decision making · 2026Article
- Long-term prognosis of pure and impure tachycardiomyopathy.ESC heart failure · 2025Observational
- Atrial fibrillation and flutter as global drivers of heart failure: Burden and longitudinal trends over three decades.ESC heart failure · 2025Article
- Exercise and Atrial Fibrillation: Current Evidence, Knowledge Gaps, and Future Directions.Reviews in cardiovascular medicine · 2025Review
- Up-titration of medication in patients with new-onset heart failure with and without atrial fibrillation.ESC heart failure · 2025Article
- Global trends and regional disparities in atrial fibrillation and flutter burden attributable to high alcohol consumption: findings from the global burden of disease study 2021.BMC cardiovascular disorders · 2025Observational
- Factors influencing the development of heart failure after PCI in patients with acute coronary syndrome: a meta-analysis.American journal of translational research · 2025Review
- Current Strategies for Atrial Fibrillation Prevention and Management: Taming the Commonest Cardiac Arrhythmia.Current vascular pharmacology · 2025Review
- Article
- The risk of stroke recurrence in patients with atrial fibrillation and reduced ejection fraction.European stroke journal · 2023Article
- Intestinal Barrier Dysfunction and Microbial Translocation in Patients with First-Diagnosed Atrial Fibrillation.Biomedicines · 2023Article
- Prevalence and prognostic role of L wave and selected clinical and echocardiographic variables in dogs with atrial fibrillation.Journal of veterinary internal medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many patients with persistent, chronic, or frequently recurring paroxysmal atrial fibrillation (AF) may develop a tachycardiomyopathy (TCM) with left ventricular (LV) dysfunction and heart failure (HF), which is reversible upon restoration and maintenance of sinus rhythm, when feasible, or via better and tighter ventricular rate (VR) control. Mechanisms involved in producing this leading cause of TCM (AF-TCM) include loss of atrial contraction, irregular heart rate, fast VR, neurohumoral activation, and structural myocardial changes. The most important of all mechanisms relates to optimal VR control, which seems to be an elusive target. Uncontrolled AF may also worsen preexisting LV dysfunction and exacerbate HF symptoms. Data, albeit less robust, also point to deleterious effects of slow VRs on LV function. Thus, a J-shaped relationship between VR and clinical outcome has been suggested, with the optimal VR control hovering at ~ 65 bpm, ranging between 60 and 80 bpm; VRs above and below this range may confer higher morbidity and mortality rates. A convergence of recent guidelines is noted towards a stricter rather than a more lenient VR control with target heart rate < 80 bpm at rest and < 110 bpm during moderate exercise which seems to prevent TCM or improve LV function and exercise capacity and relieve TCM-related symptoms and signs. Of course, restoring and maintaining sinus rhythm is always a most desirable target, when feasible, either with drugs or more likely with ablation. All these issues are herein reviewed, current guidelines are discussed and relevant data are tabulated and pictorially illustrated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.